Vipin Gard, President & CEO, Altimmune : Yes. I mean, the the good thing about these three indications is that there's a lot of overlap in terms of the mechanism, in terms of the value proposition. You're treating two different things at the same time. So it's very similar. They're all diseases that are the outcomes are worse with people with obesity and overweight.